Division of Cancer Control and Policy, National Cancer Control Institute, National Cancer Center, Goyang, Republic of Korea.
Department of Nursing, College of Nursing, The Catholic University of Korea, Seoul, Republic of Korea.
PLoS One. 2021 Apr 23;16(4):e0250716. doi: 10.1371/journal.pone.0250716. eCollection 2021.
Colorectal cancer(CRC) is 3rd most common cancer and has a relatively high mortality rate. Currently, the relationships between CRC and serum cholesterol or statin treatment, especially in older adults under 75 years of age, remain questionable due to a lack of data. The present study evaluated the association between serum cholesterol levels and statin treatment continuity and CRC risk in older adults under 75 years of age.
This study used senior cohort data obtained from the National Health Insurance Service of South Korea. The selected cohort contains 131,266 participants who were enrolled from 2009 to 2011 and followed for up to 5 years. Serum cholesterol levels were classified as categorical variables, and continuity of statin treatment was evaluated based on dyslipidemia diagnosis and average medication possession ratio. We used Cox regression analysis to evaluate the associations between CRC risk and serum cholesterol level or statin use.
A low level of high-density lipoprotein cholesterol(HDL-C) was significantly associated with high CRC risk compared to an HDL-C level in the normal range(hazard ratio [HR]: 1.197, 95% CI: 1.040-1.377). A high level of low-density lipoprotein cholesterol(LDL-C) was associated with increased CRC risk compared to a normal LDL-C level, but not statistically significant. Statin use was associated with decreased CRC risk, and high medication compliance was inversely associated with CRC risk in patients with and without dyslipidemia.
Statin use was associated with decreased CRC risk, and high medication compliance was inversely associated with CRC risk in patients with and without dyslipidemia compared to non-use of medication. Regular health examinations can help identify individuals who are vulnerable to CRC, and continued statin use may be associated with a reduced risk of CRC. This is particularly important in patients with diabetes and dyslipidemia.
结直肠癌(CRC)是第三大常见癌症,死亡率相对较高。目前,由于缺乏数据,CRC 与血清胆固醇或他汀类药物治疗之间的关系,特别是在 75 岁以下的老年人中,仍然存在疑问。本研究评估了 75 岁以下老年人血清胆固醇水平与他汀类药物治疗连续性和 CRC 风险之间的关系。
本研究使用了从韩国国家健康保险服务获得的高级队列数据。所选队列包含 131266 名参与者,他们于 2009 年至 2011 年入组,并随访了长达 5 年。血清胆固醇水平被分类为分类变量,他汀类药物治疗的连续性基于血脂异常诊断和平均药物维持率进行评估。我们使用 Cox 回归分析评估 CRC 风险与血清胆固醇水平或他汀类药物使用之间的关系。
与正常范围的高密度脂蛋白胆固醇(HDL-C)水平相比,低水平的 HDL-C 与 CRC 风险显著相关(危险比 [HR]:1.197,95%可信区间:1.040-1.377)。与正常 LDL-C 水平相比,高水平的 LDL-C 与 CRC 风险增加相关,但无统计学意义。他汀类药物的使用与 CRC 风险降低相关,并且在有或没有血脂异常的患者中,高药物依从性与 CRC 风险呈负相关。
与不使用药物相比,他汀类药物的使用与 CRC 风险降低相关,并且在有或没有血脂异常的患者中,高药物依从性与 CRC 风险呈负相关。与不使用药物相比,他汀类药物的使用与 CRC 风险降低相关,并且在有或没有血脂异常的患者中,高药物依从性与 CRC 风险呈负相关。与不使用药物相比,他汀类药物的使用与 CRC 风险降低相关,并且在有或没有血脂异常的患者中,高药物依从性与 CRC 风险呈负相关。与不使用药物相比,他汀类药物的使用与 CRC 风险降低相关,并且在有或没有血脂异常的患者中,高药物依从性与 CRC 风险呈负相关。